Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Abbott meets Street consensus

ABT reported second quarter operating EPS of $0.52, which met the Street consensus and was 6.1% above its second

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE